SAN DIEGO, Nov. 12, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced its ophthalmic formulations and outcomes from a recent economic study will be featured in presentations, courses, and related events at the annual American Academy of Ophthalmology (AAO) meeting being held in Las Vegas, Nevada on November 14–17, 2015. The American Academy of Ophthalmology is the largest national membership organization of ophthalmologists who provide comprehensive eye care to patients throughout the world. More than 90 percent of practicing ophthalmologists are AAO members, and the Academy boasts of more than 7,000 international members.
Imprimis' Dropless™ injectables and/or LessDrops™ combination drops will be discussed at several sessions during the AAO meeting.
Topics by Day and Time (Pacific Standard Time):
|
(1) |
Saturday, November 14, 11:15 am-11:22 am. |
|
Topical Steroids vs. NSAIDs: Effect on Cystoid Macular Edema Incidence after Cataract Surgery with Transzonular Medicines | |
|
Presenting author: Ahad Mahootchi, MD | |
|
Location: Sands Expo/Venetian, Bassano 2701 | |
|
(2) |
Sunday, November 15, 12:15 pm-1:45 pm. |
|
The Cutting Edge | |
|
Chair: Robert Osher, MD | |
|
Panelists: Richard Lindstrom, MD; David Chang, MD; Abhay Vasavada, MBBS FRCS; Boris Malyugin, MD, PhD; Richard Packard, MD; and Iqbal Ahmed, MD | |
|
Location: Sands Expo/Venetian, Venetian Ballroom EF | |
|
(3) |
Sunday, November 15, 2:00 pm-4:15 pm |
|
New and Emerging Technologies in Cataract and Refractive Surgery | |
|
Senior instructor: Jonathan M. Davidorf, MD | |
|
Instructors: Michael Colvard, MD; Iqbal K. Ahmed, MD, Anthony Aldave, MD; Richard Lindstrom, MD; John Doane, MD; Mark Packer, MD; Ganesha Kandavel, MD; and Nicole Fram, MD | |
|
Location: Sands Expo/Venetian, Lido 3005 | |
|
(4) |
Sunday, November 15, 3:15 pm – 5:30 pm |
|
Personalized Cataract Surgery: Femtosecond Laser, Advanced Technology IOLs, and New Devices | |
|
Senior instructor: Matteo Piovella, MD | |
|
Instructors: Jorge Alio, MD PhD; Steve Arshinoff, MD; Burkhard Dick, MD; Jack Holladay, MD MSEE FACS; Barbara Kusa, MD; and Richard Lindstrom, MD; Zoltan Nagy, MD | |
|
Location: Sands Expo/Venetian, Murano 3305 | |
|
(5) |
Monday, November 16, 2:00 pm – 4:15 pm |
|
Best of the Best: An Update in Cataract Surgery | |
|
Senior Instructor: Matteo Piovella, MD | |
|
Instructors: David Chang, MD; Steven Dell, MD; Burkhard Dick, MD; Fabrizio Camesasca, MD; Claudio Carbonara, MD; Richard Lindstrom, MD; and Steven Schallhorn, MD | |
|
Location: Sands Expo/Venetian, Venetian Ballroom C | |
|
(6) |
Monday, November 16, 2:00 pm – 4:15 pm |
|
Better Surgery through Chemicals | |
|
Senior Instructor: William G. Myers, MD | |
|
Instructors: Minas Coroneo, MBBS, MS; David Glasser, MD; Steve Arshinoff, MD; William Mieler, MD; Charles Leiter; Hiroyuki Nakashizuka, MD; Daniel Dawson, MD; Neal Shorstein, MD; John Wittpenn, Jr. MD; Jeffrey Liegner, MD; and Ramon Lorente, MD | |
|
Location: Sands Expo/Venetian, Marco Polo 706 | |
|
(7) |
Monday, November 16, 3:15 pm – 4:45 pm |
|
Hot Topics 2015 | |
|
Chair: Maria M. Aaron, MD | |
|
Panelists: Donald Tan, MD; William Trattler, MD; Shigeru Kinoshita, MD; Gustano DeMoraes, MD; Randy Kardon, MD, Steven Yeh, MD; Edward Holland, MD; Jeffrey Liegner, MD; and Bita Esmaeli, MD | |
|
Location: Sands Expo/Venetian Ballroom AB | |
|
(8) |
Tuesday, November 17, 12:45 pm – 1:45 pm |
|
Dropless Cataract Surgery Rationale, Effectiveness, and the Technique | |
|
Instructors: Jeffrey Liegner, MD; Ahad Mahootchi, MD; and Neal Shorstein, MD | |
|
Location: Sands Expo/Venetian, Galileo 1001 |
Additional information about Imprimis and its proprietary innovative ophthalmic treatment options and the events at the AAO 2015 meeting will be available to conference attendees on the showroom floor at Booth #5255.
Mark L. Baum, CEO of Imprimis stated, "It is a privilege to participate at the annual AAO 2015 meeting. Interest in our innovative ophthalmic drug formulations and other compounded formulations continues to grow and we look forward to visiting with members of the ophthalmology community, investors and business partners. This meeting provides us with the opportunity to meet with those physicians and their staff who have not yet heard our message and to hopefully win their business and to have their patients experience the benefits of Dropless Therapy and LessDrops topicals."
All Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
About Imprimis' Ophthalmic Formulations
Imprimis' proprietary ophthalmic compound formulations have been optimized for both injectable and topical applications compatible with the eye. The compounded drug formulations allow for the increased solubility of a variety of active pharmaceutical ingredients, creating small, uniform particle sizes which enable them to be combined for administered as either an injectable at the time of surgery or used as a topical eye drop post-operatively. Tri-Moxi (triamcinolone acetonide and moxifloxacin hydrochloride) and Tri-Moxi-Vanc (with added vancomycin), are available in single, injectable intraocular doses administered during ocular surgery, where as a result of surgery, there is inflammation and a chance for post-operative infection. Over 400 ophthalmologists are now prescribing Imprimis' proprietary Dropless Therapy™ compounded formulations. Since its launch in April 2014, Dropless Therapy™ formulations have been administered in over 100,000 eye surgeries, primarily cataract surgeries. Ophthalmologists have reported that Dropless Therapy formulations may substantially reduce or eliminate the need for costly eye drops following ocular surgeries thereby simplifying post-operative patient care and helping to provide safeguards against bacterial infection and inflammation. The findings of the "Analysis of the Economic Impacts of Dropless Cataract Therapy on Medicare, Medicaid, State Governments, and Patient Costs" economic study conducted by researchers at Andrew Chang & Co, LLC demonstrated that our Dropless Therapy™ could provide savings to Medicare, Medicaid and patients of up to $13 billion, with a most likely savings estimate of $8.7 billion. The co-sponsored economic study was conducted assuming the cost of Dropless Therapy™ was $100 per dose. More information is available at www.GoDropless.com.
In April 2015, Imprimis launched a portfolio of Combination Drop Therapy topical formulations which may require up to 50% fewer drops to be administered by patients and provide significant cost savings of up to 75% compared to current traditional post-surgery eye drop treatments. The LessDrops educational campaign aims to improve patient compliance and alleviate patient confusion associated with complex eye drop regimens. For more information, please visit www.LessDrops.com.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.
SAFE HARBOR
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contacts
Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704.4587
Media
Deb Holliday
deb@pascalecommunications.com
412.877.4519
Logo - http://photos.prnewswire.com/prnh/20150108/167712LOGO
SOURCE Imprimis Pharmaceuticals, Inc.